BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mansoor S, Kuppermann BD, Kenney MC. Intraocular sustained-release delivery systems for triamcinolone acetonide. Pharm Res 2009;26:770-84. [PMID: 19184374 DOI: 10.1007/s11095-008-9812-z] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Johnson TV, Bull ND, Martin KR. Neurotrophic factor delivery as a protective treatment for glaucoma. Exp Eye Res. 2011;93:196-203. [PMID: 20685205 DOI: 10.1016/j.exer.2010.05.016] [Cited by in Crossref: 58] [Cited by in F6Publishing: 65] [Article Influence: 4.8] [Reference Citation Analysis]
2 Stevenson CL, Santini JT Jr, Langer R. Reservoir-based drug delivery systems utilizing microtechnology. Adv Drug Deliv Rev 2012;64:1590-602. [PMID: 22465783 DOI: 10.1016/j.addr.2012.02.005] [Cited by in Crossref: 140] [Cited by in F6Publishing: 107] [Article Influence: 14.0] [Reference Citation Analysis]
3 Arrigo A, Bandello F. Molecular Features of Classic Retinal Drugs, Retinal Therapeutic Targets and Emerging Treatments. Pharmaceutics 2021;13:1102. [PMID: 34371793 DOI: 10.3390/pharmaceutics13071102] [Reference Citation Analysis]
4 Kambhampati SP, Kannan RM. Dendrimer nanoparticles for ocular drug delivery. J Ocul Pharmacol Ther 2013;29:151-65. [PMID: 23410062 DOI: 10.1089/jop.2012.0232] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 7.3] [Reference Citation Analysis]
5 Lee SS, Hughes PM, Robinson MR. Recent advances in drug delivery systems for treating ocular complications of systemic diseases: . Current Opinion in Ophthalmology 2009;20:511-9. [DOI: 10.1097/icu.0b013e328330ccb9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
6 Hong J, Kim BK, Lim H, Lee S, Lee SJ. Identification and characterization of triamcinolone acetonide, a microglial-activation inhibitor. Immunopharmacol Immunotoxicol 2012;34:912-8. [PMID: 22551518 DOI: 10.3109/08923973.2012.671332] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
7 Bansal P, Garg S, Sharma Y, Venkatesh P. Posterior Segment Drug Delivery Devices: Current and Novel Therapies in Development. Journal of Ocular Pharmacology and Therapeutics 2016;32:135-44. [DOI: 10.1089/jop.2015.0133] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
8 Nkanga CI, Fisch A, Rad-malekshahi M, Romic MD, Kittel B, Ullrich T, Wang J, Krause RWM, Adler S, Lammers T, Hennink WE, Ramazani F. Clinically established biodegradable long acting injectables: An industry perspective. Advanced Drug Delivery Reviews 2020;167:19-46. [DOI: 10.1016/j.addr.2020.11.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
9 García-Millán E, Quintáns-Carballo M, Otero-Espinar FJ. Improved release of triamcinolone acetonide from medicated soft contact lenses loaded with drug nanosuspensions. Int J Pharm 2017;525:226-36. [PMID: 28412447 DOI: 10.1016/j.ijpharm.2017.03.082] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
10 Bravo-Osuna I, Andrés-Guerrero V, Arranz-Romera A, Esteban-Pérez S, Molina-Martínez IT, Herrero-Vanrell R. Microspheres as intraocular therapeutic tools in chronic diseases of the optic nerve and retina. Adv Drug Deliv Rev 2018;126:127-44. [PMID: 29339146 DOI: 10.1016/j.addr.2018.01.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
11 Santos A, Sinn Aw M, Bariana M, Kumeria T, Wang Y, Losic D. Drug-releasing implants: current progress, challenges and perspectives. J Mater Chem B 2014;2:6157-82. [DOI: 10.1039/c4tb00548a] [Cited by in Crossref: 77] [Cited by in F6Publishing: 5] [Article Influence: 9.6] [Reference Citation Analysis]
12 Shah SS, Denham LV, Elison JR, Bhattacharjee PS, Clement C, Huq T, Hill JM. Drug delivery to the posterior segment of the eye for pharmacologic therapy. Expert Rev Ophthalmol 2010;5:75-93. [PMID: 20305803 DOI: 10.1586/eop.09.70] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 7.9] [Reference Citation Analysis]
13 Araújo J, Garcia ML, Mallandrich M, Souto EB, Calpena AC. Release profile and transscleral permeation of triamcinolone acetonide loaded nanostructured lipid carriers (TA-NLC): in vitro and ex vivo studies. Nanomedicine: Nanotechnology, Biology and Medicine 2012;8:1034-41. [DOI: 10.1016/j.nano.2011.10.015] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 4.8] [Reference Citation Analysis]
14 Farese E, Cennamo G, Velotti N, Traversi C, Rinaldi M, De Crecchio G. Intravitreal bevacizumab combined with grid photocoagulation in recurrent macular edema secondary to retinal vein occlusion. Eur J Ophthalmol 2014;24:761-70. [PMID: 24585424 DOI: 10.5301/ejo.5000448] [Cited by in Crossref: 6] [Article Influence: 0.8] [Reference Citation Analysis]
15 Kambhampati SP, Bhutto IA, Wu T, Ho K, McLeod DS, Lutty GA, Kannan RM. Systemic dendrimer nanotherapies for targeted suppression of choroidal inflammation and neovascularization in age-related macular degeneration. J Control Release 2021;335:527-40. [PMID: 34058271 DOI: 10.1016/j.jconrel.2021.05.035] [Reference Citation Analysis]
16 Nuzzi R, Tridico F. Glaucoma: Biological Trabecular and Neuroretinal Pathology with Perspectives of Therapy Innovation and Preventive Diagnosis. Front Neurosci 2017;11:494. [PMID: 28928631 DOI: 10.3389/fnins.2017.00494] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
17 Zarei-Ghanavati S, Malaekeh-Nikouei B, Pourmazar R, Seyedi S. Preparation, characterization, and in vivo evaluation of triamcinolone acetonide microspheres after intravitreal administration. J Ocul Pharmacol Ther 2012;28:502-6. [PMID: 22537291 DOI: 10.1089/jop.2011.0215] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
18 Gaballa SA, Kompella UB, Elgarhy O, Alqahtani AM, Pierscionek B, Alany RG, Abdelkader H. Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives. Drug Deliv Transl Res 2021;11:866-93. [PMID: 32901367 DOI: 10.1007/s13346-020-00843-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
19 Chawan-Saad J, Wu M, Wu A, Wu L. Corticosteroids for Diabetic Macular Edema. Taiwan J Ophthalmol 2019;9:233-42. [PMID: 31942428 DOI: 10.4103/tjo.tjo_68_19] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
20 Lee SS, Hughes P, Ross AD, Robinson MR. Advances in Biodegradable Ocular Drug Delivery Systems. In: Kompella UB, Edelhauser HF, editors. Drug Product Development for the Back of the Eye. Boston: Springer US; 2011. pp. 185-230. [DOI: 10.1007/978-1-4419-9920-7_9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
21 Herrero-Vanrell R, Cardillo JA, Kuppermann BD. Clinical applications of the sustained-release dexamethasone implant for treatment of macular edema. Clin Ophthalmol 2011;5:139-46. [PMID: 21383939 DOI: 10.2147/OPTH.S15783] [Cited by in Crossref: 5] [Cited by in F6Publishing: 27] [Article Influence: 0.5] [Reference Citation Analysis]
22 Li W, He B, Dai W, Zhang Q, Liu Y. Evaluations of therapeutic efficacy of intravitreal injected polylactic-glycolic acid microspheres loaded with triamcinolone acetonide on a rabbit model of uveitis. Int Ophthalmol 2014;34:465-76. [PMID: 23868505 DOI: 10.1007/s10792-013-9829-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
23 Singh RB, Ichhpujani P, Thakur S, Jindal S. Promising therapeutic drug delivery systems for glaucoma: a comprehensive review. Ther Adv Ophthalmol 2020;12:2515841420905740. [PMID: 32206746 DOI: 10.1177/2515841420905740] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
24 Pinto FC, Da Silva-Cunha Junior A, Oréfice RL, Ayres E, Andrade SP, Lima LD, Moura SA, Da Silva GR. Controlled release of triamcinolone acetonide from polyurethane implantable devices: application for inhibition of inflammatory-angiogenesis. J Mater Sci Mater Med 2012;23:1431-45. [PMID: 22466817 DOI: 10.1007/s10856-012-4615-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
25 Tamboli V, Mishra GP, Mitra AK. Novel pentablock copolymer (PLA-PCL-PEG-PCL-PLA) based nanoparticles for controlled drug delivery: Effect of copolymer compositions on the crystallinity of copolymers and in vitro drug release profile from nanoparticles. Colloid Polym Sci 2013;291:1235-45. [PMID: 23626400 DOI: 10.1007/s00396-012-2854-0] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 5.0] [Reference Citation Analysis]
26 Cho H, Kambhampati SP, Lai MJ, Zhou L, Lee G, Xie Y, Hui Q, Kannan RM, Duh EJ. Dendrimer-Triamcinolone Acetonide Reduces Neuroinflammation, Pathological Angiogenesis, and Neuroretinal Dysfunction in Ischemic Retinopathy. Adv Ther (Weinh) 2021;4:2000181. [PMID: 34527806 DOI: 10.1002/adtp.202000181] [Reference Citation Analysis]
27 Famili A, Kahook MY, Park D. A Combined Micelle and Poly(Serinol Hexamethylene Urea)- Co -Poly( N -Isopropylacrylamide) Reverse Thermal Gel as an Injectable Ocular Drug Delivery System: Micelles and Thermal Gel for Ocular Drug Delivery. Macromol Biosci 2014;14:1719-29. [DOI: 10.1002/mabi.201400250] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
28 Lee SS, Hughes P, Ross AD, Robinson MR. Biodegradable implants for sustained drug release in the eye. Pharm Res. 2010;27:2043-2053. [PMID: 20535532 DOI: 10.1007/s11095-010-0159-x] [Cited by in Crossref: 158] [Cited by in F6Publishing: 139] [Article Influence: 13.2] [Reference Citation Analysis]
29 Suresh PK, Sah AK. Nanocarriers for ocular delivery for possible benefits in the treatment of anterior uveitis: focus on current paradigms and future directions. Expert Opinion on Drug Delivery 2014;11:1747-68. [DOI: 10.1517/17425247.2014.938045] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
30 Sutradhar KB, Sumi CD. Implantable microchip: the futuristic controlled drug delivery system. Drug Deliv 2016;23:1-11. [PMID: 24758139 DOI: 10.3109/10717544.2014.903579] [Cited by in Crossref: 48] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
31 Lavik E, Kuehn MH, Kwon YH. Novel drug delivery systems for glaucoma. Eye (Lond) 2011;25:578-86. [PMID: 21475311 DOI: 10.1038/eye.2011.82] [Cited by in Crossref: 99] [Cited by in F6Publishing: 83] [Article Influence: 9.0] [Reference Citation Analysis]
32 Wade JS, Desai TA. Planar microdevices enhance transport of large molecular weight molecules across retinal pigment epithelial cells. Biomed Microdevices 2014;16:629-38. [PMID: 24789225 DOI: 10.1007/s10544-014-9865-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
33 Araújo J, Gonzalez-mira E, Egea M, Garcia M, Souto E. Optimization and physicochemical characterization of a triamcinolone acetonide-loaded NLC for ocular antiangiogenic applications. International Journal of Pharmaceutics 2010;393:168-76. [DOI: 10.1016/j.ijpharm.2010.03.034] [Cited by in Crossref: 110] [Cited by in F6Publishing: 108] [Article Influence: 9.2] [Reference Citation Analysis]
34 Boscia F. Current Approaches to the Management of Diabetic Retinopathy and Diabetic Macular Oedema: . Drugs 2010;70:2171-200. [DOI: 10.2165/11538130-000000000-00000] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
35 Mohtashami Z, Esmaili Z, Vakilinezhad MA, Seyedjafari E, Akbari Javar H. Pharmaceutical implants: classification, limitations and therapeutic applications. Pharmaceutical Development and Technology 2020;25:116-32. [DOI: 10.1080/10837450.2019.1682607] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
36 Yang Y, Bailey C, Loewenstein A, Massin P. Intravitreal corticosteroids in diabetic macular edema: pharmacokinetic considerations. Retina. 2015;35:2440-2449. [PMID: 26352555 DOI: 10.1097/iae.0000000000000726] [Cited by in Crossref: 49] [Cited by in F6Publishing: 28] [Article Influence: 8.2] [Reference Citation Analysis]
37 Altamirano-Vallejo JC, Navarro-Partida J, Gonzalez-De la Rosa A, Hsiao JH, Olguín-Gutierrez JS, Gonzalez-Villegas AC, Keller BC, Bouzo-Lopez L, Santos A. Characterization and Pharmacokinetics of Triamcinolone Acetonide-Loaded Liposomes Topical Formulations for Vitreoretinal Drug Delivery. J Ocul Pharmacol Ther 2018;34:416-25. [PMID: 29584529 DOI: 10.1089/jop.2017.0099] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
38 Pereira ADF, Pereira LGR, Barbosa LADO, Fialho SL, Pereira BG, Patricio PSDO, Pinto FCH, Da Silva GR. Efficacy of methotrexate-loaded poly( ε -caprolactone) implants in Ehrlich solid tumor-bearing mice. Drug Delivery 2013;20:168-79. [DOI: 10.3109/10717544.2013.801052] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
39 Kambhampati SP, Mishra MK, Mastorakos P, Oh Y, Lutty GA, Kannan RM. Intracellular delivery of dendrimer triamcinolone acetonide conjugates into microglial and human retinal pigment epithelial cells. Eur J Pharm Biopharm 2015;95:239-49. [PMID: 25701805 DOI: 10.1016/j.ejpb.2015.02.013] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
40 García-Millán E, Koprivnik S, Otero-Espinar FJ. Drug loading optimization and extended drug delivery of corticoids from pHEMA based soft contact lenses hydrogels via chemical and microstructural modifications. Int J Pharm 2015;487:260-9. [PMID: 25891253 DOI: 10.1016/j.ijpharm.2015.04.037] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 6.9] [Reference Citation Analysis]